Show simple item record

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMATHIEU, Clement
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEZIN, Julien
ORCID: 0000-0002-2568-1928
IDREF: 181595710
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
dc.date.accessioned2025-07-08T13:25:41Z
dc.date.available2025-07-08T13:25:41Z
dc.date.issued2025-05-18
dc.identifier.issn1941-7225en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/207273
dc.description.abstractEnBACKGROUND: The COVID-19 pandemic disrupted healthcare access, potentially impacting cardiovascular prevention by increasing and worsening interruptions in antihypertensive treatment. In this context, we aimed to assess whether the epidemic had modified the effect of antihypertensive interruptions on the risk of major cardiovascular events (MACE). METHODS: From the nationwide SNDS French health insurance databases (2018/01/01-2021/12/31), we identified patients with ≥1 year of continuous antihypertensive drug use. We then constituted a group of patients who interrupted an antihypertensive during the period (interrupters) i.e. who presented with a treatment gap for at least one antihypertensive (entry date: interruption date). Interruption length defined was defined as time to treatment restart. After 1:1 matching, we constituted a second group of patients with continuous antihypertensive treatment at interrupters entry date (persisters; entry date: interrupter entry date). Associations between MACE risk, antihypertensive drug interruption (all durations, ≥15 days, ≥30 days), COVID epidemic period, and the interaction between these were assessed using GEE multivariable models. RESULTS: A total of 2,072,672 interrupter/persister pairs were included (4,145,344 patients; 43.6% in COVID period). Risk of MACE was not found increased after interruptions overall (OR=0.99; 95%CI [0.97-1.02]); it was when interruptions lasted at least fifteen days (OR=1.03 [1.01-1.06]) and during the COVID period independently of the existence of interruptions (OR=1.44 [1.39-1.50]; p-value for interaction: all interruptions 0.69, exceeding 15 days 0.65). CONCLUSIONS: The COVID epidemic period was associated with an increased risk of MACE or all-cause death in antihypertensive drug users without worsening the effect of antihypertensive drug interruptions.
dc.language.isoENen_US
dc.subject.enCOVID-19
dc.subject.enMACE
dc.subject.enSNDS
dc.subject.enAntihypertensive
dc.subject.enDrug Interruption
dc.title.enEffect of the COVID-19 epidemic on the association between antihypertensive drug interruption and the risk of major cardiovascular event in France
dc.title.alternativeAm J Hypertensen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/ajh/hpaf085en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed40382781en_US
bordeaux.journalAmerican Journal of Hypertensionen_US
bordeaux.pagehpaf085en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-05151232
hal.version1
hal.date.transferred2025-07-08T13:25:43Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=American%20Journal%20of%20Hypertension&rft.date=2025-05-18&rft.spage=hpaf085&rft.epage=hpaf085&rft.eissn=1941-7225&rft.issn=1941-7225&rft.au=MATHIEU,%20Clement&BEZIN,%20Julien&PARIENTE,%20Antoine&rft.genre=article


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record